- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04174105
Gene Transfer Study in Patients With Late Onset Pompe Disease (FORTIS)
A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients With Late Onset Pompe Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study (FORTIS) will evaluate the safety and efficacy of an investigational gene replacement therapy, AT845, in adult subjects with LOPD. Subjects will receive a single dose of AT845 delivered via intravenous (IV) infusion.
Up to 3 nominal dose levels of AT845 are planned to be evaluated in this study. A single AT845 administration via IV infusion is planned for each subject. The initial dosing cohort received a single dose of 3x10^13 vg/kg of AT845. The second dose cohort will receive a single dose of 6×10^13 vg/kg. The third dose cohort will receive a single dose of 1×10^14 vg/kg. Dose escalation between cohorts will be based on evaluations of safety and in consultation with the independent DMC.
There will be a core observation period of 48 weeks with scheduled visits and assessments. Following the conclusion of the core observation period, subjects will be seen every 6 months for a safety follow-up visit for up to 5 years postdose.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Astellas Pharma Global Development, Inc.
- Phone Number: 800-888-7704
- Email: Astellas.registration@astellas.com
Study Locations
-
-
-
Newcastle upon Tyne, United Kingdom, NE1 4LP
- Recruiting
- Newcastle Upon Tyne Hospitals Foundation Trust Clinical Research Facility
-
Contact:
- Ellie Drummond
- Phone Number: 0191 241 8601
-
Contact:
-
-
-
-
California
-
Orange, California, United States, 92868
- Recruiting
- University of California Irvine, Department of Neurology
-
Palo Alto, California, United States, 94304
- Recruiting
- Stanford University
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- Recruiting
- University of Utah, Division of Medical Genetics
-
Principal Investigator:
- Nicola Longo, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject is aged ≥ 18 years (ambulatory or nonambulatory).
- Subject has a documented clinical diagnosis of Pompe disease by genetic testing.
- Subject has received enzyme replacement therapy (ERT) with rhGAA for the previous ≥ 2 years.
- Subject has been on a stable standard dose (at least 20 mg/kg every 2 weeks) of ERT with rhGAA for at least the previous 6 months.
- Subject has upright FVC ≥ 30% of predicted normal value.
- Subject or legally authorized representative(s) (LAR) (if applicable) provides written informed consent.
- Subject and LAR(s) are willing and able to comply with study visits and study procedures.
- Subject must agree to refrain from blood or blood products donation and sperm or egg donation from the time of AT845 administration until the later of 90 days or 3 consecutive negative viral shedding samples
Exclusion Criteria:
- Subject is currently participating in an interventional study or has received gene or cell therapy.
- Subject tests positive for AAV8 antibodies with titers >1:20 neutralizing.
- Subject has received immune-modulating agents within 90 days before dosing (use of inhaled corticosteroids is allowed); use of other concomitant medications to manage chronic conditions must have been stable for at least 30 days before dosing. Concomitant medications that may predispose the subject to peripheral neuropathy will be evaluated.
- Subject has any clinically significant laboratory values (other than those directly associated with LOPD [e.g., GAA, serum creatine kinase (CK)]) that would preclude participation in the study.
- Subject has clinically significant underlying liver disease at Screening, or has any of the following:
- Gamma glutamyl transferase (GGT) > 5.0 x upper limit of normal (ULN)
- Active hepatitis B or C, and hepatitis B surface antigen (HBsAg), HB core antibody (HBcAb), HBV-DNA positivity or HCV-RNA viral load positivity, respectively.
- Negative viral load assays in 2 samples, collected at least 6 months apart, will be required to be considered negative. Both natural clearers and those who have cleared HCV on antiviral therapy are eligible.
- Currently on antiviral therapy for hepatitis B or C
- Subject has serological or viral load evidence of HIV-1 or HIV-2.
- Subject has received drugs for treatment of myopathy or neuropathy with immunosuppressive therapy (e.g., corticosteroids, cyclosporine, tacrolimus, methotrexate, cyclophosphamide, IV immunoglobulin, rituximab) within 3 months prior to starting the study
- Subject has a high risk for a severe allergic reaction to rhGAA (ie, previous moderate to severe anaphylactic reaction to alglucosidase alfa or and/or a history of sustained high immunoglobulin G [IgG] antibody titers to alglucosidase alfa that suggests a high risk for an allergic reaction to ERT).
- Subject has a history of hypersensitivity to β2 agonist drugs such as albuterol, levalbuterol, bitolterol, pirbuterol, terbutaline, salmeterol, which contraindicates pulmonary function testing.
- Subject has an active viral infection based on clinical observation.
- Subject has a history of or concurrent medical condition other than Pompe disease that could jeopardize safety of the subject or impact study results.
- Subject has a history of, or currently has, a clinically important cardiac condition, such as an echocardiogram (ECHO) with ejection fraction below 40% or has symptoms or signs of cardiomyopathy that precludes enrollment.
- Subject has a contraindication to study drug or to corticosteroids, or has demonstrated hypersensitivity to any of the components of the study drug.
- Subject tests positive for GAA antibodies with titers > 1:50,000 total
- Subject has a history of hypersensitivity to MRI contrast agents including gadolinium.
- Subject has a known hypersensitivity to local anesthetics such as lidocaine.
- Subject has a bleeding diathesis, e.g., due to anti-coagulation or anti-platelet treatments.
- Subject has a concurrent medical condition (including uncontrolled diabetes, alcohol use disorder, certain autoimmune conditions, Lyme disease, active malignancy requiring chemotherapy and/or radiation, uremic nephropathy, known exposure to heavy metals) commonly associated with peripheral neuropathy. Other concurrent medical conditions that may predispose to peripheral neuropathy will be evaluated and action taken on a case-by-case basis, following discussion between the Investigator and Medical Monitor.
- Subject has a history of diagnosed peripheral neuropathy or an abnormal NCS and/or mISS that is consistent with peripheral neuropathy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Initial Dose Cohort
3x10^13 vg/kg of AT845 administered via intravenous infusion
|
AT845 is an AAV8 vector delivering a functional copy of the human GAA gene, under the control of a muscle-specific promoter
Other Names:
|
Experimental: Second Dose Cohort
6x10^13 vg/kg of AT845 administered via intravenous infusion
|
AT845 is an AAV8 vector delivering a functional copy of the human GAA gene, under the control of a muscle-specific promoter
Other Names:
|
Experimental: Third Dose Cohort
1x10^14 vg/kg of AT845 administered via intravenous infusion
|
AT845 is an AAV8 vector delivering a functional copy of the human GAA gene, under the control of a muscle-specific promoter
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GAA enzymatic activity
Time Frame: Baseline and Week 12
|
Change from baseline in GAA enzymatic activity in muscle biopsies at week 12
|
Baseline and Week 12
|
GAA protein expression
Time Frame: Baseline and Week 12
|
Change from baseline in GAA protein expression in muscle biopsies at week 12.
|
Baseline and Week 12
|
Safety and Tolerability over time
Time Frame: Change from baseline and up to month 60
|
Frequency of adverse events (AEs), serious adverse events (SAEs), and changes from baseline in relevant clinical laboratory tests
|
Change from baseline and up to month 60
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vector Copy Number
Time Frame: Baseline and Week 12
|
Change from baseline in vector copy number (VCN) in muscle biopsies at week 12
|
Baseline and Week 12
|
Thigh Fat Fraction
Time Frame: Baseline and Month 18
|
Change from baseline in thigh fat fraction by MRI
|
Baseline and Month 18
|
The Gait, Stairs, Gower Maneuver, Chair (GSGC)
Time Frame: Baseline, Week 24 and Week 48
|
The GSGC is a composite test that evaluates both the time to perform different motor activities and qualitatively measures motor function.
|
Baseline, Week 24 and Week 48
|
Forced Vital Capacity (FVC)
Time Frame: Baseline, Week 24 and Week 48
|
Change from baseline in percentage of predicted FVC measured by pulmonary function testing
|
Baseline, Week 24 and Week 48
|
Maximum Inspiratory Pressure (MIP)
Time Frame: Baseline, Week 24 and Week 48
|
Change from baseline in MIP measured by pulmonary function testing
|
Baseline, Week 24 and Week 48
|
Maximum Expiratory Pressure (MEP)
Time Frame: Baseline, Week 24 and Week 48
|
Change from baseline in MEP measured by pulmonary function testing
|
Baseline, Week 24 and Week 48
|
EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Questionnaire
Time Frame: Baseline and Week 48
|
Change from baseline in health profiles and overall health status as assessed by the EQ-5D-5L
|
Baseline and Week 48
|
Rasch-built Pompe-specific Activity (R-PAct) scale
Time Frame: Baseline and Week 48
|
Change from baseline in the R-PAct scale, which was developed to measure Pompe patients' ability carry out daily life activities and social participation
|
Baseline and Week 48
|
6-Minute Walk Test (for ambulatory patients)
Time Frame: Baseline, Week 24 and Week 48
|
Change from baseline in the distance walked in the 6 minute walk test (6MWT), which is a standardized assessment of how far an individual can walk on a hard, flat surface in a period of 6 minutes
|
Baseline, Week 24 and Week 48
|
Patient-Reported Outcomes Measurement Information System (PROMIS)
Time Frame: Baseline and Week 48
|
Change from baseline in scores of PROMIS short forms for fatigue, physical function, social participation and sleep disturbance
|
Baseline and Week 48
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Medical Director, Astellas Pharma Global Development, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Genetic Diseases, Inborn
- Carbohydrate Metabolism, Inborn Errors
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Lysosomal Storage Diseases, Nervous System
- Glycogen Storage Disease
- Glycogen Storage Disease Type II
Other Study ID Numbers
- AT845-01
- 2019-003595-38 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pompe Disease (Late-onset)
-
University of Erlangen-Nürnberg Medical SchoolRecruitingPompe Disease (Late-onset) | Pompe Disease | Pompe's Disease Juvenile Onset | Pompe Disease Infantile-OnsetGermany
-
Indiana UniversityNational Institute on Aging (NIA)RecruitingDementia | Alzheimer Disease, Late OnsetUnited States
-
University of MinnesotaMayo Clinic; National Institute on Aging (NIA); University of St ThomasCompletedAlzheimer's Disease, Late OnsetUnited States
-
NeuroEM Therapeutics, Inc.Invicro, Boston; Byrd Alzheimer's Institute, University of South Florida; University... and other collaboratorsCompletedAlzheimer Disease | Alzheimer Disease, Late OnsetUnited States
-
Federal University of Minas GeraisCompletedAlzheimer Disease, Late Onset
-
Ohio State UniversityCompletedAlzheimer Disease, Late OnsetUnited States
-
NeuroEM Therapeutics, Inc.University of South Florida Health / Byrd Alzheimer's InstituteUnknownAlzheimer Disease | Alzheimer Disease, Late OnsetUnited States
-
Universitaire Ziekenhuizen KU LeuvenUnknownAlzheimer Disease, Late OnsetBelgium
-
IRCCS Centro San Giovanni di Dio FatebenefratelliI.R.C.C.S. Fondazione Santa Lucia; Ministero della Salute, ItalyRecruitingAlzheimer Disease | Alzheimer Disease, Late Onset | Cognitive DeteriorationItaly
-
Tamir Ben-HurHebrew University of JerusalemEnrolling by invitationAlzheimer Disease, Late OnsetIsrael